SCHOTT Pharmaceutical Packaging has announced plans to increase production capacity at its Zavolzhe plant by more than 50%, in a bid to continue its growth in Russia.
SCHOTT board of management chairman professor Udo Ungeheuer said expanding the company’s presence in Russia constitutes a major step for the benefit of its customers.
"We are seeing continued growth in demand for locally manufactured primary packaging that also meets all of the international standards for quality. This will result in shorter delivery routes and better export opportunities for our customers," Ungeheuer said.
Following a consistent investment strategy is an attempt by the company to help its customers in the Russian pharmaceutical industry to achieve their own growth and quality objectives.
In recent years, the Russian pharmaceutical industry has experienced double-digit growth, and state initiatives such as the government’s ‘Pharma 2020’ strategy that seeks to encourage local manufacturing of medications will continue the development according to the Good Manufacturing Practice (GMP) standard.
In 2011, SCHOTT opened a new GMP-compliant pharmaceutical packaging plant.
"GMP will be required by law for all companies that manufacture in Russia starting in 2014 and SCHOTT has the necessary know-how on helping its customers to establish GMP-certified manufacturing thanks to its 125 years of experience and global manufacturing network," Ungeheuer concluded.
SCHOTT Pharmaceutical Systems supplies glass tubing and primary packaging for the pharmaceutical industry.
The company has five glass tubing production sites and fifteen sites for pharmaceutical packaging spread over four continents.
Image: SCHOTT Pharmaceutical Systems will increase packaging capacity at its Zavolzhe plant in Russia by more than 50%. Credit: SCHOTT